The underwriters of the offering will have the option to buy another 1.3 million shares to cover any over allotments.
In January KaloBios said it intended to sell 3.9 million shares for $12 to $14 per share.
The company is based in South San Francisco, Calif., and it is studying antibacterial drugs and treatments for cystic fibrosis and blood cancers.
|